Protamines
-
Subject Areas on Research
- A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
- A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
- A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
- A reliable, nondestructive animal model for interstitial cystitis: intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride.
- Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab.
- Adaptive force sonorheometry for assessment of whole blood coagulation.
- Adverse reactions to protamine.
- Anaphylactic/anaphylactoid reactions during cardiac surgery.
- Antibodies against heparin-protamine complexes: Effect and clinical relevance.
- Antibody formation after drug administration during cardiac surgery: parameters for aprotinin use.
- Anticoagulant therapy during cardiopulmonary bypass.
- Anticoagulation and reversal paradigms: is too much of a good thing bad?
- Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.
- Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial.
- Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management.
- Development of universal antidotes to control aptamer activity.
- Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).
- Do anticoagulation with heparin and protamine reversal alter thrombogenicity of coated and noncoated pulmonary artery catheters?
- Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: a randomised, controlled study.
- Effects of protamine on histamine release from human lung.
- Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.
- Evaluation of patients at risk for protamine reactions.
- Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
- Hematologic changes occurring with cardiac catheterization.
- Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery.
- Hemostatic agents and their safety.
- Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery.
- Heparin modifies the immunogenicity of positively charged proteins.
- Heparin neutralization by recombinant platelet factor 4 and protamine.
- Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass.
- Heparinase I (neutralase) reversal of systemic anticoagulation.
- High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.
- Histone H1 enhances the DNA binding activity of the transcription factor EmBP-1.
- Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
- Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity.
- Life-threatening reactions to intravenous protamine.
- Managing clotting: a North American perspective.
- Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease.
- Optical detection of macromolecular heparin via selective coextraction into thin polymeric films.
- Predicting and treating coagulopathies after cardiopulmonary bypass in children.
- Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature.
- Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.
- Protamine and its cardiovascular effects.
- Protamine contributes to myocardial ischemia.
- Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.
- Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
- Protamine reversal of heparin: a fishy practice?
- Protamine, is something fishy about it? The spectre of anaphylaxis continues.
- Protamine-induced immune thrombocytopenia.
- Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography.
- Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
- Spermatogenesis and the regulation of Ca(2+)-calmodulin-dependent protein kinase IV localization are not dependent on calspermin.
- Spermiogenesis and exchange of basic nuclear proteins are impaired in male germ cells lacking Camk4.
- Suspected protamine allergy: diagnosis and management for coronary artery surgery.
- The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
- The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).
- The substrate specificity of cyclic AMP-dependent protein kinase: amino acid sequences at the phosphorylation sites of herring protamine (clupeine).